389 related articles for article (PubMed ID: 30455361)
1.
Höllein A; Meggendorfer M; Dicker F; Jeromin S; Nadarajah N; Kern W; Haferlach C; Haferlach T
Blood Adv; 2018 Nov; 2(22):3118-3125. PubMed ID: 30455361
[TBL] [Abstract][Full Text] [Related]
2. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
3. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
[TBL] [Abstract][Full Text] [Related]
4. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.
Loghavi S; Zuo Z; Ravandi F; Kantarjian HM; Bueso-Ramos C; Zhang L; Singh RR; Patel KP; Medeiros LJ; Stingo F; Routbort M; Cortes J; Luthra R; Khoury JD
J Hematol Oncol; 2014 Oct; 7():74. PubMed ID: 25281355
[TBL] [Abstract][Full Text] [Related]
6. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
7. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
[TBL] [Abstract][Full Text] [Related]
8. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
[TBL] [Abstract][Full Text] [Related]
9. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.
Daver N; Liu Dumlao T; Ravandi F; Pierce S; Borthakur G; Pemmaraju N; Nazha A; Faderl S; Jabbour E; Garcia-Manero G; Cortes J; Kantarjian H; Quintás-Cardama A
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):435-40. PubMed ID: 23763915
[TBL] [Abstract][Full Text] [Related]
10. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
[TBL] [Abstract][Full Text] [Related]
11. How I diagnose and treat NPM1-mutated AML.
Falini B; Brunetti L; Martelli MP
Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
13. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
14. Genetic biomarkers identify a subgroup of high-risk patients within low-risk
Carbonell D; Suárez-González J; Chicano M; Andrés-Zayas C; Díez-Díez M; Rodríguez-Macías G; Muñiz P; Kwon M; Anguita J; Díez-Martín JL; Buño I; Martínez-Laperche C
Leuk Lymphoma; 2021 May; 62(5):1178-1186. PubMed ID: 33372822
[TBL] [Abstract][Full Text] [Related]
15. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
16. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA.
Kansal R
Hum Pathol; 2019 Aug; 90():80-96. PubMed ID: 31077683
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
[TBL] [Abstract][Full Text] [Related]
19. [Effect of clonal hematopoiesis in remission on hematopoiesis recovery in patients with NPM1 mutated acute myeloid leukemia after chemotherapy].
Wang LL; Chen SN
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):845-850. PubMed ID: 38049337
[No Abstract] [Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
